Navigation Links
Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
Date:12/3/2007

TUSTIN, Calif., Dec. 3 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today announced that it will release its financial results for the second quarter of fiscal year 2008 on December 10, 2007 at 7:00 a.m. EST and will host a conference call and webcast to discuss the results at 11:30 a.m. EST on the same day.

Peregrine's senior management will discuss financial results for the quarter and will review recent operating highlights. A question-and-answer session will follow management's discussion. All interested parties are encouraged to listen to the live conference call or the live or archived webcast.

The conference call and webcast will begin at 11:30 a.m. EST/8:30 a.m. PST.

To listen to a live broadcast of the call over the Internet or to review the archived webcast, please visit: http://www.peregrineinc.com. The webcast will be archived on Peregrine's website for 30 days.

To listen to the conference call via telephone, please call the following number approximately 10 minutes prior to the scheduled start time and request to join the Peregrine Pharmaceuticals call: 1 (800) 860-2442. A telephonic replay of the conference call will be available starting approximately one hour after the conclusion of the call through December 17, 2007 by calling (877) 344-7529, passcode 382933#.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.

Contacts:

GendeLLindheim BioCom Partners

Investors Media

info@peregrineinc.com Barbara Lindheim

(800) 987-8256 (212) 918-4650


'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Feb. 11, 2016  Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) ... December 31, 2015. --> --> ... net loss of $29.3 million, or $0.34 loss per share, compared ... share for the same period in 2014. For the year ended ... million, or $1.05 loss per share, as compared to a net ...
(Date:2/11/2016)... and GERMANTOWN, Maryland , ... Frankfurt Prime Standard: QIA) today announced the introduction of ... gene expression profiling, expanding QIAGEN,s portfolio of Sample to ... researchers to select from over 20,000 human genes and ... between genes, cellular phenotypes and disease processes. --> ...
(Date:2/11/2016)... ATLANTA , Feb. 11, 2016  Spectra BioPharma ... Organization (CSO) that provides biopharma companies the experience, ... implement and deploy outsourced sales teams. Created in ... team addresses both the strategic and tactical needs ... innovative sales solutions through both personal and non-personal ...
(Date:2/11/2016)... (PRWEB) , ... February 11, ... ... business-to-business publication dedicated to delivering cutting-edge information focused on the development and ... Sciences to become a premier sponsor of the 2016 BioProcess International Awards ...
Breaking Biology Technology:
(Date:2/11/2016)... 2016  Vigilant Solutions announces today that its license plate ... by Lee,s Summit Police Department to ... arrest of a homicide suspect. Kansas City ... 65 square miles and is home to roughly 100,000 residents. ... single mobile license plate reader system and also leverages Vigilant,s ...
(Date:2/8/2016)... PRAGUE, Czech Republic , February 8, 2016 ... first EU-regulated global payment platform which presents innovation ... Voice Biometrics Authentication feature called VoiceKey. --> ... payment platform which presents innovation for clients, comfort ... feature called VoiceKey. --> Worldcore ...
(Date:2/3/2016)... , February 3, 2016 ... market research report "Automated Fingerprint Identification System Market by ... Search), Application (Banking & Finance, Government, Healthcare, and Transportation) ... MarketsandMarkets, the market is expected to be worth USD ... 21.0% between 2015 and 2020. The transformation and technology ...
Breaking Biology News(10 mins):